Jiangsu Hengrui Medicine Co Ltd
Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and… Read more
Market Cap & Net Worth: Jiangsu Hengrui Medicine Co Ltd (600276)
Jiangsu Hengrui Medicine Co Ltd (SHG:600276) has a market capitalization of $47.91 Billion (CN¥351.55 Billion) as of March 18, 2026. Listed on the SHG stock exchange, this China-based company holds position #719 globally and #17 in its home market, demonstrating a 2.59% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jiangsu Hengrui Medicine Co Ltd's stock price CN¥55.11 by its total outstanding shares 6379002274 (6.38 Billion).
Jiangsu Hengrui Medicine Co Ltd Market Cap History: 2015 to 2026
Jiangsu Hengrui Medicine Co Ltd's market capitalization history from 2015 to 2026. Data shows growth from $12.89 Billion to $47.91 Billion (13.55% CAGR).
Index Memberships
Jiangsu Hengrui Medicine Co Ltd is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Shanghai Shenzhen CSI 300
CSI300
|
$1.21 Trillion | 2.33% | #5 of 285 |
|
FTSE China A50
FTXIN9
|
$525.16 Billion | 5.37% | #5 of 50 |
Weight: Jiangsu Hengrui Medicine Co Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Jiangsu Hengrui Medicine Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jiangsu Hengrui Medicine Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.43x
Jiangsu Hengrui Medicine Co Ltd's market cap is 1.43 times its annual revenue
1.01x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
6.30x
Jiangsu Hengrui Medicine Co Ltd's market cap is 6.30 times its annual earnings
10.29x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $12.89 Billion | $9.32 Billion | $2.17 Billion | 1.38x | 5.93x |
| 2016 | $14.36 Billion | $11.09 Billion | $2.59 Billion | 1.29x | 5.55x |
| 2017 | $26.20 Billion | $13.84 Billion | $3.22 Billion | 1.89x | 8.15x |
| 2018 | $26.09 Billion | $17.42 Billion | $4.07 Billion | 1.50x | 6.42x |
| 2019 | $52.14 Billion | $23.29 Billion | $5.33 Billion | 2.24x | 9.79x |
| 2020 | $79.91 Billion | $27.73 Billion | $6.33 Billion | 2.88x | 12.63x |
| 2021 | $43.75 Billion | $25.91 Billion | $4.53 Billion | 1.69x | 9.66x |
| 2022 | $33.38 Billion | $21.28 Billion | $3.91 Billion | 1.57x | 8.55x |
| 2023 | $39.32 Billion | $22.82 Billion | $4.30 Billion | 1.72x | 9.14x |
| 2024 | $39.91 Billion | $27.98 Billion | $6.34 Billion | 1.43x | 6.30x |
Competitor Companies of 600276 by Market Capitalization
Companies near Jiangsu Hengrui Medicine Co Ltd in the global market cap rankings as of March 18, 2026.
Key companies related to Jiangsu Hengrui Medicine Co Ltd by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #423 globally with a market cap of $51.97 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #455 globally with a market cap of $47.47 Billion USD.
- United Therapeutics Corporation (NASDAQ:UTHR): Ranked #915 globally with a market cap of $21.40 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #423 | Zoetis Inc | NYSE:ZTS | $51.97 Billion | $118.15 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.46 |
| #455 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #915 | United Therapeutics Corporation | NASDAQ:UTHR | $21.40 Billion | $534.30 |
Jiangsu Hengrui Medicine Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Jiangsu Hengrui Medicine Co Ltd's market cap moved from $12.89 Billion to $ 47.91 Billion, with a yearly change of 13.55%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥47.91 Billion | -7.49% |
| 2025 | CN¥51.79 Billion | +29.78% |
| 2024 | CN¥39.91 Billion | +1.48% |
| 2023 | CN¥39.32 Billion | +17.80% |
| 2022 | CN¥33.38 Billion | -23.71% |
| 2021 | CN¥43.75 Billion | -45.25% |
| 2020 | CN¥79.91 Billion | +53.27% |
| 2019 | CN¥52.14 Billion | +99.81% |
| 2018 | CN¥26.09 Billion | -0.41% |
| 2017 | CN¥26.20 Billion | +82.42% |
| 2016 | CN¥14.36 Billion | +11.45% |
| 2015 | CN¥12.89 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Jiangsu Hengrui Medicine Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $47.91 Billion USD |
| MoneyControl | $47.91 Billion USD |
| MarketWatch | $47.91 Billion USD |
| marketcap.company | $47.91 Billion USD |
| Reuters | $47.91 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.